Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment

Figure 10  Overexpression of leucine-rich repeat-containing 19 sensitizes colorectal cancer cells to oxaliplatin. A and B: Western blot analysis of leucine-rich repeat-containing 19 (LRRC19) protein expression in HCT116 and HT29 cells treated with various concentrations (0, 5, 10 μM and 0, 20, 40 μM) of oxaliplatin for 48 hours; C-F: Morphological assessment under inverted microscopy of cell death induced by oxaliplatin treatment at concentrations of 0, 5, 10, 20, 40, and 80 μM in HCT116 (Vector), HCT116 (LRRC19), HT29 (Vector), and HT29 (LRRC19) cells after 48 hours of exposure.